ASX December health sector winners… and a 91pc drop for a trial-flopped stock
The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024 Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in December after …